Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Pasi, K. J., Collins, Peter William, Keeling, D. M., Brown, S. A., Cumming, A. M., Dolan, G. C., Hay, C. R. M., Hill, F. G. H., Laffan, M. and Peake, I. R. 2004. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10 (3) , pp. 218-231. 10.1111/j.1365-2516.2004.00886.x

Full text not available from this repository.


von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: blood products; 1-deamino-8-d-arginine vasopressin; guideline; inherited bleeding disorder; treatment; von Willebrand disease
Publisher: Wiley-Blackwell
ISSN: 1351-8216
Last Modified: 04 Jun 2017 06:28

Citation Data

Cited 130 times in Google Scholar. View in Google Scholar

Cited 117 times in Scopus. View in Scopus. Powered By Scopus® Data

Cited 71 times in Web of Science. View in Web of Science.

Actions (repository staff only)

Edit Item Edit Item